Immunocore (IMCR) Expected to Announce Earnings on Wednesday

Immunocore (NASDAQ:IMCR) is anticipated to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Immunocore to post earnings of ($0.31) per share and revenue of $87.63 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Immunocore Stock Performance

Immunocore stock opened at $29.99 on Tuesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore has a fifty-two week low of $27.69 and a fifty-two week high of $72.56. The firm’s fifty day moving average price is $29.99 and its 200-day moving average price is $32.03. The stock has a market cap of $1.50 billion, a P/E ratio of -31.57 and a beta of 0.77.

Analyst Upgrades and Downgrades

Several research firms recently commented on IMCR. Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 target price (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 target price on shares of Immunocore in a report on Friday, January 10th. Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $72.00 to $38.00 in a report on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Immunocore in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.